Research programme: anti-glucose transporter recombinant monoclonal antibodies - Avalon GloboCare/Massachusetts Institute of Technology
Alternative Names: QTY anti-glucose transporter antibodiesLatest Information Update: 03 Nov 2022
At a glance
- Originator Avalon GloboCare; Massachusetts Institute of Technology
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Glucose transporter type 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research T-cell leukaemia
Most Recent Events
- 29 Sep 2022 Avalon GloboCare and Massachusetts Institute of Technology file for patent protection with US PTO for QTY glucose transporter technology in USA
- 29 Sep 2022 Early research in T-cell leukaemia in USA (unspecified route)
- 21 May 2019 Avalon GloboCare and Massachusetts Institute of Technology sign research and co-development agreement for therapeutics for T-cell leukaemia